National Institute Of Arthritis And Musculoskeletal And Skin Diseases (niams)
Clinical trials sponsored by National Institute Of Arthritis And Musculoskeletal And Skin Diseases (niams), explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Scientists probe how eczema drugs alter skin microbes Results expected Jan 2027 (estimated)
- Lupus drug may harm ovaries – could a hormone shot help? Results expected May 2027 (estimated)
- Lupus drug may shield heart and arteries Results expected Aug 2027 (estimated)
-
Promising psoriasis drug study for rare muscle disease pulled before start
Disease control CancelledThis study planned to test deucravacitinib, a drug already approved for psoriasis, in adults with hard-to-treat dermatomyositis (DM) or juvenile dermatomyositis (JDM). Participants would have taken a pill twice daily for 24 weeks, with clinic visits every 4 weeks. However, the st…
Phase 2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC